ID: ALA318243

Max Phase: Preclinical

Molecular Formula: C38H43N3O6

Molecular Weight: 637.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCCC(Oc2ccc(C(=O)Nc3ccccc3OCCCC(=O)O)cc2)c2ccccc2)CC1

Standard InChI:  InChI=1S/C38H43N3O6/c1-45-36-16-8-6-14-33(36)41-26-24-40(25-27-41)23-9-17-34(29-11-3-2-4-12-29)47-31-21-19-30(20-22-31)38(44)39-32-13-5-7-15-35(32)46-28-10-18-37(42)43/h2-8,11-16,19-22,34H,9-10,17-18,23-28H2,1H3,(H,39,44)(H,42,43)

Standard InChI Key:  DXJABSUQJDCZLA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 637.78

Molecular Weight (Monoisotopic): 637.3152

AlogP: 6.91

#Rotatable Bonds: 16

Polar Surface Area: 100.57

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.90

CX Basic pKa: 8.03

CX LogP: 3.99

CX LogD: 3.92

Aromatic Rings: 4

Heavy Atoms: 47

QED Weighted: 0.13

Np Likeness Score: -0.88

References

1. Yoshida K, Horikoshi Y, Eta M, Chikazawa J, Ogishima M, Fukuda Y, Sato H..  (1998)  Synthesis of benzanilide derivatives as dual acting agents with alpha 1-adrenoceptor antagonistic action and steroid 5-alpha reductase inhibitory activity.,  8  (21): [PMID:9873656] [10.1016/s0960-894x(98)00538-1]

Source

Source(1):

• Scientific Literature